EUVIMEDEUVIMED entdecken
Crossref

A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma

Wei Zhou, Hao Chi, Xiaohu Zhao, Guangrong Tao, Jianhe Gan

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03669-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Wei Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Mutation, Transcription Factors. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The prognosis of hepatocellular carcinoma (HCC) is poor and there is no stable and reliable molecular biomarker for evaluation. This study attempted to find reliable prognostic markers from tumor mutational profiles. METHODS: A total of 362 HCC samples with whole-exome sequencing were collected as discovery datasets, and 200 samples with targeted sequencing were used for validation of the relevant results. All HCC samples were obtained from previously published studies. Bayesian non-negative matrix factorization was used to extract mutational signatures, and multivariate Cox regression models were utilized to identify the prognostic role of mutational factors. Gene set enrichment analysis was employed to discover potential signaling pathways associated with specific mutational groups. RESULTS: In the HCC discovery dataset, a total of four mutational signatures (i.e., signatures 4, 6, 16, and 22) were extracted, of which signature 16 characterized by T>C mutations was observed to be associated with favorable HCC prognosis, and this correlation was also found in the validation dataset. Further analysis showed that patients with ARID1A mutations exhibited inferior survival outcomes in both discovery and validation datasets. Mechanistic exploration revealed that the presence of signature 16 was associated with better immune infiltration and tumor immunogenicity, while patients with ARID1A mutations were away from these favorable immunological features. CONCLUSION: By integrating somatic mutation data and clinical information of HCC, this study identified that signature 16 and ARID1A mutations were associated with better and worse outcomes respectively, providing a basis for prognosis prediction and clinical treatment strategies of HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularMutationTranscription FactorsDNA-Binding ProteinsBiomarkers, TumorHumansPrognosisMaleFemaleMiddle AgedExome SequencingAged

Stichwörter der Autor:innen

ARID1A mutationHepatocellular carcinomaImmunityMutational signature 16Survival outcome

Substanzen

ARID1A protein, humanTranscription FactorsDNA-Binding ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China.
  • Department of Medical Laboratory, Huaian Hospital of Huaian City, Huaian, China.
  • Department of Infectious Diseases, Huaian Hospital of Huaian City, Huaian, China.
  • Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China. lipingliping999@126.com.

Zitieren

APA

Zhou, W., Chi, H., Zhao, X., Tao, G., & Gan, J. (2024). A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03669-0

Vancouver

Zhou W, Chi H, Zhao X, Tao G, Gan J. A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03669-0

BibTeX
@article{Zhou2024,
  author = {Zhou, Wei and Chi, Hao and Zhao, Xiaohu and Tao, Guangrong and Gan, Jianhe},
  title = {A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03669-0}
}
Kostenlos starten →